HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...

Additionally, with the growing demand for chronic disease treatments and the ageing baby boomer population, the infusion market is set for significant growth. According to the market research ...

GP369, a monoclonal antibody directed against the extracellular ligand-binding structural domain of FGFR2, showed promising results in FGFR2-IIIb subtype of breast cancer cell lines, demonstrating ...